Durezol®
Difluprednate 0.05% · ophthalmic emulsion
Steroid
Approved uses
Inflammation and pain after ocular surgery
1 drop QID beginning 24 hours after surgery through the first 2 postoperative weeks, then BID for 1 week, then taper based on response
Anterior chamber cells and pain clear by day 8, with a clinically significant IOP rise in 3%.
Endogenous anterior uveitis
1 drop QID for 14 days, then taper as clinically indicated
QID matches prednisolone acetate 1% eight times daily on day-14 cell clearing.
OFF-LABELNot in the FDA label for this product
Non-infectious anterior scleritis
4 or more drops per day initially as the single treatment agent, tapered on response
Retrospective series · n=25
Retrospective interventional case series of 25 patients (35 eyes) treated with difluprednate as the single agent. 83% of eyes reached clinical resolution, at a median of 6 weeks. Eyes started at 4 or more times daily were more likely to resolve (hazard ratio 3.43, 95% CI 1.19 to 9.88, P=0.02). 9 eyes developed IOP elevation (defined as 24 mmHg or higher), 4 eyes lost 2 or more lines of BCVA with 1 of those from cataract progression, and 1 eye needed cataract surgery. Uncontrolled and retrospective; the authors conclude only that it may effectively treat non-infectious anterior scleritis with a tolerable side effect profile.
Contraindications
- Most active viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella.
- Mycobacterial infection of the eye.
- Fungal disease of ocular structures.
0.05% emulsion (difluprednate 0.5 mg/mL), 5 mL in an 8 mL bottle
Difluprednate is a corticosteroid. There is no generally accepted explanation for the mechanism of action of ocular corticosteroids; they are thought to act by inducing phospholipase A2 inhibitory proteins (lipocortins), which are postulated to control the biosynthesis of prostaglandins and leukotrienes by inhibiting release of their common precursor arachidonic acid. Corticosteroids inhibit edema, fibrin deposition, capillary dilation, leukocyte migration, capillary and fibroblast proliferation, collagen deposition, and scar formation associated with inflammation, and may delay or slow healing. Deacetylated in vivo to the active metabolite 6-alpha,9-difluoroprednisolone 17-butyrate; after 2 drops QID for 7 days blood levels of that metabolite stayed below the 50 ng/mL quantification limit in all subjects, so systemic absorption is limited.
Warnings & Precautions
- IOP elevation and glaucoma: Prolonged corticosteroid use may produce glaucoma with optic nerve damage and defects in visual acuity and visual fields; use with caution in the presence of glaucoma and routinely monitor IOP if the product is used 10 days or longer.
- Posterior subcapsular cataract: Corticosteroid use may produce it.
- Delayed healing: The use of corticosteroids after cataract surgery may delay healing and increase the incidence of bleb formation. The initial prescription and renewal of the medication order beyond 28 days should be made by a physician only after examination with magnification, such as slit lamp biomicroscopy, and where appropriate, fluorescein staining.
- Corneal and scleral melting: Various ocular diseases and long-term use of topical corticosteroids have been known to cause corneal and scleral thinning, and in diseases causing thinning, perforations have been known to occur with topical steroids; use in the presence of thin corneal or scleral tissue may lead to perforation of the globe.
- Secondary ocular infection: Prolonged use may suppress host response and increase the hazard of secondary ocular infection; in acute purulent conditions steroids may mask infection or enhance existing infection, and the patient should be reevaluated if signs and symptoms fail to improve after 2 days.
- Viral infection exacerbation: Ocular steroids may prolong the course and worsen the severity of many ocular viral infections including herpes simplex; a history of herpes simplex requires great caution, and frequent slit lamp microscopy is recommended.
- Fungal keratitis: Fungal corneal infection is particularly prone to develop coincidentally with long-term local steroid use; consider fungal invasion in any persistent corneal ulceration where a steroid has been used or is in use, and culture when appropriate.
- Topical ophthalmic use: Not indicated for intraocular administration.
- Risk of contamination: Do not allow the dropper tip to touch the eye, eyelids, or any surface, as this may contaminate the emulsion.
- Contact lens wear: The anti-microbial preservative, sorbic acid 0.1%, may be absorbed by soft contact lenses. Do not instill while wearing contact lenses; remove them before instillation, and they may be reinserted after 10 minutes.
Common Side Effects
After ocular surgery, reactions in 5% to 15% of subjects were corneal edema, ciliary and conjunctival hyperemia, eye pain, photophobia, posterior capsule opacification, anterior chamber cells, anterior chamber flare, conjunctival edema, and blepharitis, and reactions in 1% to 5% were reduced visual acuity, punctate keratitis, eye inflammation, and iritis; most of these reactions may have been the consequence of the surgical procedure. In endogenous anterior uveitis, reactions in 5% to 10% of subjects were blurred vision, eye irritation, eye pain, headache, increased IOP, iritis, limbal and conjunctival hyperemia, punctate keratitis, and uveitis, and reactions in 2% to 5% were anterior chamber flare, corneal edema, dry eye, iridocyclitis, photophobia, and reduced visual acuity.
Pregnancy: There are no available data on use in pregnant women, and systemic exposure is expected to be minimal after topical ocular administration. Subcutaneous difluprednate in pregnant rabbits during organogenesis produced maternal toxicity, embryofetal lethality, fetal growth retardation, and teratogenicity (cleft palate, cerebral hernia, exencephaly, and others) at 10 mcg/kg/day, about 0.97-fold the MRHOD, with a NOEL of 1 mcg/kg/day. In rats it decreased placental weight at 10 mcg/kg/day or more, and decreased weight gain and delayed ossification of the fetus were seen at 100 mcg/kg/day; dosing from late gestation through lactation caused no abnormalities in postnatal development, growth, behavior, or reproductive potential.
Lactation: There are no data on presence in human milk, effects on the breastfed infant, or effects on milk production. Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. Systemic exposure of a breastfeeding woman is expected to be minimal following topical ocular administration, but the possibility of harm to the breastfed child cannot be ruled out; weigh the benefits of breastfeeding with the mother's clinical need for DUREZOL and any potential adverse effects on the breast-fed child from DUREZOL or from the underlying maternal condition.
A 3-month trial in 79 patients aged 0 to 3 years treated for inflammation following cataract surgery showed a safety profile similar to prednisolone acetate 1%.